Fluvoxamine API Manufacturers

Looking for Fluvoxamine API 54739-18-3?

Description:

Here you will find a list of producers, manufacturers and distributors of Fluvoxamine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Fluvoxamine 

Synonyms:

Fluvoxamina , Fluvoxamine , Fluvoxaminum , Fluvoxaminum maleas  

Cas Number:

54739-18-3 

DrugBank number:

DB00176 

Unique Ingredient Identifier:

O4L1XPO44W

Fluvoxamine is a type of Serotonin reuptake inhibitors

Serotonin reuptake inhibitors (SRIs) are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various mental health conditions. These medications work by specifically targeting the serotonin transporter protein, inhibiting its function and thereby increasing the concentration of serotonin in the synaptic cleft.

SRIs are commonly prescribed for the management of depression, anxiety disorders, obsessive-compulsive disorder (OCD), and other related conditions. By blocking the reuptake of serotonin, SRIs enhance serotonin neurotransmission, which plays a crucial role in regulating mood, emotions, and cognition.

This class of API includes well-known drugs such as fluoxetine, sertraline, paroxetine, and escitalopram, among others. They are typically administered orally and exhibit good bioavailability, allowing for effective systemic distribution.

The therapeutic effects of SRIs are achieved by modulating the delicate balance of serotonin in the brain. By preventing its reuptake, SRIs ensure that serotonin remains available for longer periods, leading to increased activation of postsynaptic serotonin receptors. This neurochemical modulation results in improved mood, reduced anxiety, and alleviation of related symptoms.

Serotonin reuptake inhibitors are generally well-tolerated, but they may have potential side effects such as nausea, gastrointestinal disturbances, sexual dysfunction, and sleep disturbances. However, these effects are often manageable and vary among individuals.

Overall, serotonin reuptake inhibitors are a crucial class of pharmaceutical APIs widely utilized in the treatment of mental health disorders. Their ability to modulate serotonin levels effectively makes them valuable tools in improving patients' quality of life and well-being.

Fluvoxamine (Serotonin reuptake inhibitors), classified under Central Nervous System Agents

Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.

CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.

The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.

Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.

• Duchefa Farma B.V. from Netherlands, product country of origin India
• Sinoway industrial Co.,Ltd from China, product country of origin China
• Shandong Octagon Chemicals Limited from China, product country of origin China
• TIEFENBACHER API + Ingredients from Germany, product country of origin Unknown
• Teva API from Israel, product country of origin Unknown
• Sun Pharma from India, product country of origin India
• ZCL Chemicals from India, product country of origin India
• Medichem from Spain, product country of origin Unknown

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.